COMMUNIQUÉS West-GlobeNewswire

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
30/05/2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease [...]
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
30/05/2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company [...]
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30/05/2024
Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to [...]
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
30/05/2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board [...]
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
30/05/2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment [...]
Health Catalyst to Participate in Upcoming Investor Conferences
30/05/2024
SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
30/05/2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ [...]
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
30/05/2024
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases Nomlabofusp was selected based on potential for clinical benefit [...]
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
30/05/2024
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive [...]
Ardelyx, Inc. Reports Employment Inducement Grants
30/05/2024
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Korro to Participate in Upcoming June Investor and Scientific Conferences
30/05/2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences: [...]
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
30/05/2024
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing [...]
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
30/05/2024
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m. ET [...]
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
30/05/2024
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The [...]
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30/05/2024
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Smart for Life to Attend IFT FIRST, the Premier Food Science and Technology Event
30/05/2024
Industry Leader and Board Member Heather Granato to Explore Acquisition and Strategic Partnership Opportunities Setting Stage for SMFL Future Growth and Innovation MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- Smart for Life [...]
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
30/05/2024
PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
BioAdaptives, Inc. Welcomes Gimhana Dissanayake to Its Board of Directors
30/05/2024
We are confident that Gimhana’s leadership will significantly enrich our board’s talent and expertise, propelling us to new heights. LAS VEGAS, May 30, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT [...]
Ipsen announces the launch of an employee shareholding plan
30/05/2024
Ipsen announces the launch of an employee shareholding plan PARIS, FRANCE, 30 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the launch of an employee shareholding plan. The fourth transaction in the last [...]

Pages